Novo Hosts Post-approval Rybelsus Investor Call; Semaglutide HFpEF Study?
Here is a brief preview of this blast: Novo Nordisk hosted an investor call to discuss the recent Rybelsus FDA approval (previous FENIX insight). Unsurprisingly, much of the investor call discussion centered around Rybelsus pricing and market access. Below, FENIX provides a Rybelsus pricing and website analysis as well as thoughts on Novo's commentary regarding a potential semaglutide HFpEF study.